Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Caterpillar Inc (CAT) vs Enveric Biosciences Inc (ENVB) Price & Performance

Caterpillar IncTrade
Enveric Biosciences IncTrade

Price performance (Past 24H)

Key statistics

Caterpillar Inc vs Enveric Biosciences Inc — how do they compare? Caterpillar Inc trades at $941.79 (market cap $429.89B), while Enveric Biosciences Inc trades at $1.28 (market cap $5.32M). The key difference: Caterpillar Inc is far larger — about 80806.4× Enveric Biosciences Inc's market cap, and Caterpillar Inc pays a 0.7% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals.

CATENVB
Market Cap
$429.89B$5.32M
Sector
IndustrialsHealth
52-Week High
$1.06K$17.40
52-Week Low
$404.64$1.28
Enterprise Value
$468.88B$408.82K
Dividend Yield
0.7%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Caterpillar Inc

Caterpillar (CAT) trades at $931.47, down 2.2% on the day, but has gained 51% year-to-date, driven by strong earnings beats and AI-related infrastructure demand. The stock shows a bullish moving average signal but neutral overall technicals, with support near $922. Revenue reached $67.59 billion in 2025, with a net income margin of 13.33%, though valuation multiples like a P/E of 46.48 appear elevated. Recent news highlights its role in the AI data center boom, with the Power & Energy segment seeing significant backlog growth.

The outlook remains positive given analyst consensus and AI-driven tailwinds, but high valuation and exposure to economic cycles pose risks. With 55% of analysts rating it a Buy and a consensus price target of $1,030, upside potential exists, though investors should weigh margin pressures and debt levels against growth catalysts from data center and infrastructure spending.

Enveric Biosciences Inc

ENVB trades at $1.33, down 1.48% on the day, with a bearish technical signal from moving averages despite neutral oscillators. The company shows significant financial challenges with negative ROE of -257.95% and ROA of -218.01%, though it has consistently beaten earnings expectations in recent quarters. Recent news highlights active participation in investor conferences and progress with EB-003 drug candidate development.

While analyst consensus is 75% buy-rated, the stock faces substantial fundamental risks from negative profitability and cash burn. Investment opportunity exists if clinical developments succeed, but shareholders should weigh high operational losses against potential biotech breakthroughs in the neuroplastogenic therapeutics space.

Returns comparison

Trailing returns across standard periods

About Caterpillar Inc

Caterpillar Inc. designs, manufactures, and markets construction, mining, and forestry machinery. The Company also manufactures engines and other related parts for its equipment, and offers financing and insurance. Caterpillar distributes its products through a worldwide organization of dealers.

Read more on CAT

About Enveric Biosciences Inc

Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.

Read more on ENVB